Blood concentrations of synthetic cannabinoids

References

• United Nations Office on Drugs and Crime (UNODC). Current NPS Threats. Volume II, January 2020. UNODC Laboratory and Scientific Section, Vienna, 2020. Available from: https://www.unodc.org/documents/scientific/Current_NPS_Threats_Volume_II_Web.pdf
   Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction and Europol. EU Drug Markets Report. 2019. Publications Office of the European Union, Luxembourg, 2019. Available from: http://www.emcdda.europa.eu/system/files/publications/12078/20192630_TD0319332ENN_PDF.pdf
   Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. Perspectives on drugs. Synthetic cannabinoids in Europe. EMCDDA, Lisbon, 2017. Available from: http://www.emcdda.europa.eu/system/files/publications/2753/POD_Synthetic%20cannabinoids_0.pdf
   Google Scholar
• Giorgetti A, Mogler L, Haschimi B, et al. Detection and phase I metabolism of the 7-azaindole-derived synthetic cannabinoid 5F-AB-P7AICA including a preliminary pharmacokinetic evaluation. Drug Test Anal. 2020;12(1):78–91.
   PubMed Web of Science ®Google Scholar
• Kakehashi H, Shima N, Ishikawa A, et al. Effects of lipophilicity and functional groups of synthetic cannabinoids on their blood concentrations and urinary excretion. Forensic Sci Int. 2020;307:110106.
   PubMed Web of Science ®Google Scholar
• Kaneko S. Motor vehicle collisions caused by the 'super-strength' synthetic cannabinoids, MAM-2201, 5F-PB-22, 5F-AB-PINACA, 5F-AMB and 5F-ADB in Japan experienced from 2012 to 2014. Forensic Toxicol. 2017;35(2):244–251.
   PubMed Web of Science ®Google Scholar
• Peterson BL, Couper FJ. Concentrations of AB-CHMINACA and AB-PINACA and driving behavior in suspected impaired driving cases. J Anal Toxicol. 2015;39(8):642–647.
   PubMed Web of Science ®Google Scholar
• Abouchedid R, Hudson S, Thurtle N, et al. Analytical confirmation of synthetic cannabinoids in a cohort of 179 presentations with acute recreational drug toxicity to an Emergency Department in London, UK in the first half of 2015. Clin Toxicol (Phila). 2017;55(5):338–345.
   PubMed Web of Science ®Google Scholar
• WHO. 5F-APINACA (5F-AKB-48). Review Report. Agenda item 4.10. Expert Committee on Drug Dependence. Thirty-eighth Meeting, Geneva, 14–18. 2016.
   Google Scholar
• Karinen R, Tuv SS, Øiestad EL, et al. Concentrations of APINACA, 5F-APINACA, UR-144 and its degradant product in blood samples from six impaired drivers compared to previous reported concentrations of other synthetic cannabinoids. Forensic Sci Int. 2015;246:98–103.
   PubMed Web of Science ®Google Scholar
• Shanks KG, Behonick GS. Death after use of the synthetic cannabinoid 5F-AMB. Forensic Sci Int. 2016;262:e21–e24.
   PubMed Web of Science ®Google Scholar
• Hess C, Stockhausen S, Kernbach-Wighton G, et al. Death due to diabetic ketoacidosis: induction by the consumption of synthetic cannabinoids? Forensic Sci Int. 2015;257:e6–e11.
   PubMed Web of Science ®Google Scholar
• Kubo SI, Waters B, Hara K, et al. A report of novel psychoactive substances in forensic autopsy cases and a review of fatal cases in the literature. Leg Med (Tokyo). 2017;26:79–85.
   PubMed Web of Science ®Google Scholar
• Giorgetti A, Mogler L, Halter S, et al. Four cases of death involving the novel synthetic cannabinoid 5F-Cumyl-PEGACLONE. Forensic Toxicol. 2020;38(2):314–326.
   Web of Science ®Google Scholar
• Halter S, Angerer V, Röhrich J, et al. Cumyl-PEGACLONE: a comparatively safe new synthetic cannabinoid receptor agonist entering the NPS market? Drug Test Anal. 2019;11(2):347–349.
   PubMed Web of Science ®Google Scholar
• WHO. Critical Review Report: 5F-MDMB-PICA. Expert Committee on Drug Dependence. Forty-second Meeting, Geneva, 21–25. 2019.
   Google Scholar
• Malec D, Masełko J, Wachholz P, et al. Przypadek śmiertelnego zatrucia syntetycznym kannabinoidem 5F-MDMB-PICA. XXXVI Konferencja Toksykologów Sądowych, Olsztyn, 6–8. 2019.
   Google Scholar
• Sykutera M, Cychowska M, Dropiewska-Nowak A, et al. Zgon po przyjęciu 5F-MDMB-PICA: opis przypadku. XVIII Zjazd PTMSiK, 18–20. 2019.
   Google Scholar
• Truver MT, Watanabe S, Åstrand A, et al. 5F-MDMB-PICA metabolite identification and cannabinoid receptor activity. Drug Test Anal. 2020;12(1):127–135.
   PubMed Web of Science ®Google Scholar
• Boland DM, Reidy LJ, Seither JM, et al. Forty-three fatalities involving the synthetic cannabinoid, 5-Fluoro-ADB: forensic pathology and toxicology implications. J Forensic Sci. 2020;65(1):170–182.
   PubMed Web of Science ®Google Scholar
• Katselou M, Papoutsis I, Nikolaou P, et al. Diphenidine: a dissociative NPS makes an entrance on the drug scene. Forensic Toxicol. 2018;36(2):233–242.
   Web of Science ®Google Scholar
• Langford AM, Bolton JR. Synthetic cannabinoids: variety is definitely not the spice of life. J Forensic Leg Med. 2018;59:36–38.
   PubMed Web of Science ®Google Scholar
• Ong RS, Kappatos DC, Russell SGG, et al. Simultaneous analysis of 29 synthetic cannabinoids and metabolites, amphetamines, and cannabinoids in human whole blood by liquid chromatography-tandem mass spectrometry - a New Zealand perspective of use in 2018. Drug Test Anal. 2020;12(2):195–214.
   PubMed Web of Science ®Google Scholar
• Usui K, Fujita Y, Kamijo Y, et al. Identification of 5-fluoro ADB in human whole blood in four death cases. J Anal Toxicol. 2018;42(2):e21–e25.
   PubMed Web of Science ®Google Scholar
• Kusano M, Zaitsu K, Taki K, et al. Fatal intoxication by 5F-ADB and diphenidine: Detection, quantification, and investigation of their main metabolic pathways in humans by LC/MS/MS and LC/Q-TOFMS. Drug Test Anal. 2018;10(2):284–293.
   PubMed Web of Science ®Google Scholar
• Yeter O, Öztürk YE. Detection and quantification of 5F-ADB and its methyl ester hydrolysis metabolite in fatal intoxication cases by liquid chromatography-high resolution mass spectrometry. Forensic Sci Int. 2019;302:109866.
   PubMed Web of Science ®Google Scholar
• Yeter O, Öztürk YE. Metabolic profiling of synthetic cannabinoid 5F-ADB by human liver microsome incubations and urine samples using high-resolution mass spectrometry. Drug Test Anal. 2019;11(6):847–858.
   PubMed Web of Science ®Google Scholar
• Seither JZ, Reidy LJ, Boland DM. Identification and quantification of 5-Fluoro ADB and the 5-Fluoro ADB ester hydrolysis metabolite in postmortem blood samples by LC-MS/MS. J Anal Toxicol. 2020;44(2):133–139.
   PubMed Web of Science ®Google Scholar
• Angerer V, Jacobi S, Franz F, et al. Three fatalities associated with the synthetic cannabinoids 5F-ADB, 5F-PB-22, and AB-CHMINACA. Forensic Sci Int. 2017;281:e9–e15.
   PubMed Web of Science ®Google Scholar
• Ivanov ID, Stoykova S, Ivanova E, et al. A case of 5F-ADB/FUB-AMB abuse: drug-induced or drug-related death? Forensic Sci Int. 2019;297:372–377.
   PubMed Web of Science ®Google Scholar
• Capron B. 5F-ADB drivers in the State of Washington. ToxTalk. 2016;40(2):23–26.
   Google Scholar
• Minakata K, Nozawa H, Yamagishi I, et al. Sensitive quantification of 5F-NNEI and characterization of its several metabolites in authentic urine and/or serum specimens obtained from three individuals by LC–QTRAP-MS/MS and high-resolution LC–Orbitrap-MS/MS. Forensic Toxicol. 2018;36(2):498–505.
   Web of Science ®Google Scholar
• Hill SL, Dunn M, Cano C, et al. Human toxicity caused by indole and indazole carboxylate synthetic cannabinoid receptor agonists: from horizon scanning to notification. Clin Chem. 2018;64(2):346–354.
   PubMed Web of Science ®Google Scholar
• Abouchedid R, Ho JH, Hudson S, et al. Acute toxicity associated with use of 5F-derivations of synthetic cannabinoid receptor agonists with analytical confirmation. J Med Toxicol. 2016;12(4):396–401.
   PubMed Web of Science ®Google Scholar
• Hess C, Murach J, Krueger L, et al. Simultaneous detection of 93 synthetic cannabinoids by liquid chromatography-tandem mass spectrometry and retrospective application to real forensic samples. Drug Test Anal. 2017;9(5):721–733.
   PubMed Web of Science ®Google Scholar
• Behonick G, Shanks KG, Firchau DJ, et al. Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22. J Anal Toxicol. 2014;38(8):559–562.
   PubMed Web of Science ®Google Scholar
• Kronstrand R, Roman M, Andersson M, et al. Toxicological findings of synthetic cannabinoids in recreational users. J Anal Toxicol. 2013;37(8):534–541.
   PubMed Web of Science ®Google Scholar
• Gieron J, Adamowicz P. Fatal poisoning with the synthetic cannabinoid AB-CHMINACA and ethyl alcohol – a case study and literature review. Problems Forensic Sci. 2016;106:482–495.
   Google Scholar
• Maeda H, Kikura-Hanajiri R, Kawamura M, et al. AB-CHMINACA induced sudden death from non-cardiogenic pulmonary edema. Clin Toxicol (Phila). 2017;56:1–3.
   PubMed Web of Science ®Google Scholar
• Paul ABM, Simms L, Amini S, et al. Teens and spice: a review of adolescent fatalities associated with synthetic cannabinoid use. J Forensic Sci. 2018;63(4):1321–1324.
   PubMed Web of Science ®Google Scholar
• Hermanns-Clausen M, Müller D, Kithinji J, et al. Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA. Clin Toxicol (Phila)). 2018;56(6):404–411.
   PubMed Web of Science ®Google Scholar
• Tyndall JA, Gerona R, De Portu G, et al. An outbreak of acute delirium from exposure to the synthetic cannabinoid AB-CHMINACA. Clin Toxicol (Phila)). 2015;53(10):950–956.
   PubMed Web of Science ®Google Scholar
• Romańczuk A, Rojek S, Kula K, et al. Aspects related to analysis and medico-legal assessment in the context of the presence of synthetic cannabinoids in biological material based on the example of AB-CHMINACA. Arch Med Sadowej Kryminol. 2018;68(4):266–280.
   PubMedGoogle Scholar
• Neuman K. Synthetic cannabinoids in drivers: a comparison based on drug recognition expert (DRE) evaluations. ToxTalk. 2015;39(4):13–15.
   Google Scholar
• Vaiano F, Busardò FP, Palumbo D, et al. A novel screening method for 64 new psychoactive substances and 5 amphetamines in blood by LC-MS/MS and application to real cases. J Pharm Biomed Anal. 2016;129:441–449.
   PubMed Web of Science ®Google Scholar
• Lam RPK, Tang MHY, Leung SC, et al. Supraventricular tachycardia and acute confusion following ingestion of e-cigarette fluid containing AB-FUBINACA and ADB-FUBINACA: a case report with quantitative analysis of serum drug concentrations. Clin Toxicol (Phila)). 2017;55(7):662–667.
   PubMed Web of Science ®Google Scholar
• Yamagishi I, Minakata K, Nozawa H, et al. A case of intoxication with a mixture of synthetic cannabinoids EAM-2201, AB-PINACA and AB-FUBINACA, and a synthetic cathinone α-PVP. Leg Med (Tokyo). 2018;35:44–49.
   PubMed Web of Science ®Google Scholar
• Thornton SL, Akpunonu P, Glauner K, et al. Unintentional pediatric exposure to a synthetic cannabinoid (AB-PINACA) resulting in coma and intubation. Ann Emerg Med. 2015;66(3):343–344.
   PubMed Web of Science ®Google Scholar
• Hasegawa K, Wurita A, Minakata K, et al. Postmortem distribution of MAB-CHMINACA in body fluids and solid tissues of a human cadaver. Forensic Toxicol. 2015;33(2):380–387.
   PubMed Web of Science ®Google Scholar
• Adamowicz P, Gieroń J. Acute intoxication of four individuals following use of the synthetic cannabinoid MAB-CHMINACA. Clin Toxicol (Phila). 2016;54(8):650–654.
   PubMed Web of Science ®Google Scholar
• Chan S, Wu J, Lee B. Fatalities related to new psychoactive substances in Singapore-A case series. Forensic Sci Int. 2019;304:109892.
   PubMed Web of Science ®Google Scholar
• Shanks KG, Clark W, Behonick G. Death associated with the use of the synthetic cannabinoid ADB-FUBINACA. J Anal Toxicol. 2016;40(3):236–239.
   PubMed Web of Science ®Google Scholar
• Kovács K, Kereszty É, Berkecz R, et al. Fatal intoxication of a regular drug user following N-ethyl-hexedrone and ADB-FUBINACA consumption. J Forensic Leg Med. 2019;65:92–100.
   PubMed Web of Science ®Google Scholar
• Nacca N, Schult R, Loflin R, et al. Coma, seizures, atrioventricular block, and hypoglycemia in an ADB-FUBINACA body-packer. J Emerg Med. 2018;55(6):788–791.
   PubMed Web of Science ®Google Scholar
• Schwartz MD, Trecki J, Edison LA, et al. A common source outbreak of severe delirium associated with exposure to the novel synthetic cannabinoid ADB-PINACA. J Emerg Med. 2015;48(5):573–580.
   PubMed Web of Science ®Google Scholar
• Tournebize J, Gibaja V, Kahn JP. Acute effects of synthetic cannabinoids: Update 2015. Subst Abus. 2017;38(3):344–366.
   PubMed Web of Science ®Google Scholar
• Zaitsu K, Nakayama H, Yamanaka M, et al. High-resolution mass spectrometric determination of the synthetic cannabinoids MAM-2201, AM-2201, AM-2232, and their metabolites in postmortem plasma and urine by LC/Q-TOFMS. Int J Legal Med. 2015;129(6):1233–1245.
   PubMed Web of Science ®Google Scholar
• Schaefer N, Peters B, Bregel D, et al. A fatal case involving several synthetic cannabinoids. Toxichem. Krimtech. 2015;80:248–251.
   Google Scholar
• Lehmann S, Schulze B, Thomas A, et al. Organ distribution of 4-MEC, MDPV, methoxetamine and α-PVP: comparison of QuEChERS and SPE. Forensic Toxicol. 2018;36(2):320–333.
   Web of Science ®Google Scholar
• Wikström M, Thelander G, Dahlgren M, et al. An accidental fatal intoxication with methoxetamine. J Anal Toxicol. 2013;37(1):43–46.
   PubMed Web of Science ®Google Scholar
• Tynon M, Homan J, Kacinko S, et al. Rapid and sensitive screening and confirmation of thirty-four aminocarbonyl/carboxamide (NACA) and arylindole synthetic cannabinoid drugs in human whole blood. Drug Test Anal. 2017;9(6):924–934.
   PubMed Web of Science ®Google Scholar
• Alhadi S, Tiwari A, Vohra R, et al. High times, low sats: diffuse pulmonary infiltrates associated with chronic synthetic cannabinoid use. J Med Toxicol. 2013;9(2):199–206.
   PubMedGoogle Scholar
• Musshoff F, Madea B, Kernbach-Wighton G, et al. Driving under the influence of synthetic cannabinoids ("Spice"): a case series. Int J Legal Med. 2014;128(1):59–64.
   PubMed Web of Science ®Google Scholar
• Tuv SS, Krabseth H, Karinen R, et al. Prevalence of synthetic cannabinoids in blood samples from Norwegian drivers suspected of impaired driving during a seven weeks period. Accid Anal Prev. 2014;62:26–31.
   PubMed Web of Science ®Google Scholar
• Yeakel JK, Logan BK. Blood synthetic cannabinoid concentrations in cases of suspected impaired driving. J Anal Toxicol. 2013;37(8):547–551.
   PubMed Web of Science ®Google Scholar
• Hutter M, Moosmann B, Kneisel S, et al. Characteristics of the designer drug and synthetic cannabinoid receptor agonist AM-2201 regarding its chemistry and metabolism. J Mass Spectrom. 2013;48(7):885–894.
   PubMed Web of Science ®Google Scholar
• Knittel JL, Holler JM, Chmiel JD, et al. Analysis of parent synthetic cannabinoids in blood and urinary metabolites by liquid chromatography tandem mass spectrometry. J Anal Toxicol. 2016;40(3):173–186.
   PubMed Web of Science ®Google Scholar
• Rojek S, Kłys M, Maciów-Głąb M, et al. A new challenge in forensic toxicology exemplified by a case of murder under the influence of a synthetic cannabinoid - AM-2201. Leg Med (Tokyo). 2017;27:25–31.
   PubMed Web of Science ®Google Scholar
• Kneisel S, Speck M, Moosmann B, et al. LC/ESI-MS/MS method for quantification of 28 synthetic cannabinoids in neat oral fluid and its application to preliminary studies on their detection windows. Anal Bioanal Chem. 2013;405(14):4691–4706.
   PubMed Web of Science ®Google Scholar
• Patton AL, Chimalakonda KC, Moran CL, et al. K2 toxicity: fatal case of psychiatric complications following AM2201 exposure. J Forensic Sci. 2013;58(6):1676–1680.
   PubMed Web of Science ®Google Scholar
• Kneisel S, Auwärter V. Analysis of 30 synthetic cannabinoids in serum by liquid chromatography-electrospray ionization tandem mass spectrometry after liquid-liquid extraction. J Mass Spectrom. 2012;47(7):825–835.
   PubMed Web of Science ®Google Scholar
• Elian AA, Hackett J. Analysis of AM-2201 and metabolites in a drugs and driving case. Drug Test Anal. 2014;6(4):389–395.
   PubMed Web of Science ®Google Scholar
• Dziadosz M, Klintschar M, Teske J. Mixed consumption of cannabis and "Spice". Forensic Sci Int. 2014;235:e1–e2.
   PubMed Web of Science ®Google Scholar
• Holm NB, Pineda R, Andersen DW, et al. Screening of Danish traffic cases for synthetic cannabinoids in whole blood by LC-MS/MS. Scand J Forensic Sci. 2013;19(2):45–37.
   Google Scholar
• Labay LM, Caruso JL, Gilson TP, et al. Synthetic cannabinoid drug use as a cause or contributory cause of death. Forensic Sci Int. 2016;260:31–39.
   PubMed Web of Science ®Google Scholar
• Castaneto MS, Gorelick DA, Desrosiers NA, et al. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014;144:12–41.
   PubMed Web of Science ®Google Scholar
• Hermanns-Clausen M, Kneisel S, Szabo B, et al. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction. 2013;108(3):534–544.
   PubMed Web of Science ®Google Scholar
• Minakata K, Hasegawa K, Nozawa H, et al. Sensitive quantification of BB-22 and its metabolite BB-22 3-carboxyindole, and characterization of new metabolites in authentic urine and/or serum specimens obtained from three individuals by LC-QTRAP-MS/MS and high-resolution LC-Orbitrap-MS/MS. Forensic Toxicol. 2019;37(1):164–173.
   PubMed Web of Science ®Google Scholar
• Gardin A, Kucher K, Kiese B, et al. Cannabinoid receptor agonist 13, a novel cannabinoid agonist: first in human pharmacokinetics and safety. Drug Metab Dispos. 2009;37(4):827–833.
   PubMed Web of Science ®Google Scholar
• El Zahran T, Gerona R, Morgan BW, et al. A novel synthetic cannabinoid (Cumyl-4-cyano-BINACA) resulting in hyperthermia, rhabdomyolysis, and renal failure in a 29-year-old patient: it's not meningitis. Clin Toxicol (Phila). 2019;57(6):421–422.
   PubMed Web of Science ®Google Scholar
• Yeter O. Identification of the synthetic cannabinoid 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA) in plant material and quantification in post-mortem blood samples. J Anal Toxicol. 2017;41(9):720–728.
   PubMed Web of Science ®Google Scholar
• Nash C, Glowacki L, Gerostamoulos D, et al. Identification of a thermal degradation product of CUMYL-PEGACLONE and its detection in biological samples. Drug Test Anal. 2019;11(10):1480–1485.
   PubMed Web of Science ®Google Scholar
• Aknouche F, Ameline A, Richeval C, et al. Testing for SGT-151 (CUMYL-PEGACLONE) and its metabolites in blood and urine after surreptitious administration. J Anal Toxicol. 2020;44(1):75–80.
   PubMed Web of Science ®Google Scholar
• Jaenicke NJ, Pogoda W, Paulke A, et al. Retrospective analysis of synthetic cannabinoids in serum samples-epidemiology and consumption patterns. Forensic Sci Int. 2014;242:81–87.
   PubMed Web of Science ®Google Scholar
• Dresen S, Kneisel S, Weinmann W, et al. Development and validation of a liquid chromatography-tandem mass spectrometry method for the quantitation of synthetic cannabinoids of the aminoalkylindole type and methanandamide in serum and its application to forensic samples. J Mass Spectrom. 2011;46(2):163–171.
   PubMed Web of Science ®Google Scholar
• Shanks K, Dahn T, Terrell A. Detection of JWH-018 and JWH-073 by UPLC-MS-MS in postmortem whole blood casework. J Anal Toxicol. 2012;36(3):145–152.
   PubMed Web of Science ®Google Scholar
• Chung H, Lee J, Kim E. Trends of novel psychoactive substances (NPSs) and their fatal cases. Forensic Toxicol. 2016;34(1):1–11.
   Web of Science ®Google Scholar
• Canning J, Ruha AM, Pierce R, et al. Severe GI distress after smoking JWH-018. Clin. Toxicol. (Phila.). 2010;48:618.
   Web of Science ®Google Scholar
• Hermanns-Clausen M, Kneisel S, Hutter M, et al. Acute intoxication by synthetic cannabinoids-four case reports. Drug Test Anal. 2013;5(9-10):790–794.
   PubMed Web of Science ®Google Scholar
• Teske J, Weller JP, Fieguth A, et al. Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci. 2010;878(27):2659–2663.
   PubMed Web of Science ®Google Scholar
• Kacinko SL, Xu A, Homan JW, et al. Development and validation of a liquid chromatography-tandem mass spectrometry method for the identification and quantification of JWH-018, JWH-073, JWH-019, and JWH-250 in human whole blood. J Anal Toxicol. 2011;35(7):386–393.
   PubMed Web of Science ®Google Scholar
• Toennes SW, Geraths A, Pogoda W, et al. Pharmacokinetic properties of the synthetic cannabinoid JWH-018 and of its metabolites in serum after inhalation. J Pharm Biomed Anal. 2017;140:215–222.
   PubMed Web of Science ®Google Scholar
• Öztürk YE, Yeter O, Alpertunga B. Validation of JWH-018 and its metabolites in blood and urine by UPLC-MS/MS: Monitoring in forensic cases. Forensic Sci Int. 2015;248:88–93.
   PubMed Web of Science ®Google Scholar
• WHO. JWH‐018 Critical Review Report. Agenda item 4.5. Expert Committee on Drug Dependence Thirty‐sixth Meeting Geneva, 16–20. 2014.
   Google Scholar
• Baselt R. Disposition of toxic drugs and chemicals in man. 11th ed. Seal Beach, CA: Biomedical Publications; 2017.
   Google Scholar
• Yap S, Drummer OH. Prevalence of new psychoactive substances in Victorian fatally-injured drivers. Aust J Forensic Sci. 2016;48(2):230–243.
   Web of Science ®Google Scholar
• Hermanns-Clausen M, Kithinji J, Spehl M, et al. Adverse effects after the use of JWH-210 - a case series from the EU Spice II plus project. Drug Test Anal. 2016;8(10):1030–1038.
   PubMed Web of Science ®Google Scholar
• Saito T, Namera A, Miura N, et al. A fatal case of MAM-2201 poisoning. Forensic Toxicol. 2013;31(2):333–337.
   Web of Science ®Google Scholar
• Derungs A, Schwaninger AE, Mansella G, et al. Symptoms, toxicities, and analytical results for a patient after smoking herbs containing the novel synthetic cannabinoid MAM-2201. Forensic Toxicol. 2013;31(1):164–171.
   Web of Science ®Google Scholar
• Lonati D, Buscaglia E, Papa P, et al. MAM-2201 (analytically confirmed) intoxication after "Synthacaine" consumption. Ann Emerg Med. 2014;64(6):629–632.
   PubMed Web of Science ®Google Scholar
• Adamowicz P. Fatal intoxication with synthetic cannabinoid MDMB-CHMICA. Forensic Sci Int. 2016;261:e5.
   PubMed Web of Science ®Google Scholar
• Westin AA, Frost J, Brede WR, et al. Sudden cardiac death following use of the synthetic cannabinoid MDMB-CHMICA. J Anal Toxicol. 2016;40(1):86–87.
   PubMed Web of Science ®Google Scholar
• Gaunitz F, Lehmann S, Thomas A, et al. Post-mortem distribution of the synthetic cannabinoid MDMB-CHMICA and its metabolites in a case of combined drug intoxication. Int J Legal Med. 2018;132(6):1645–1657.
   PubMed Web of Science ®Google Scholar
• Bäckberg M, Tworek L, Beck O, et al. Analytically confirmed intoxications involving MDMB-CHMICA from the STRIDA project. J Med Toxicol. 2017;13(1):52–60.
   PubMed Web of Science ®Google Scholar
• Seywright A, Torrance HJ, Wylie FM, et al. Analysis and clinical findings of cases positive for the novel synthetic cannabinoid receptor agonist MDMBCHMICA. Clin Toxicol. 2016;54(8):632–637.
   PubMed Web of Science ®Google Scholar
• Kronstrand R, Tyrkko E, Lindstedt D, et al. Poster P103: MMB-CHMINACA blood concentrations in recreational users and fatal intoxications. Paper presented at the 53rd the International Association of Forensic Toxicologists (TIAFT) meeting, 2015. Firenze, Italy.
   Google Scholar
• Angerer V, Franz F, Schwarze B, et al. Reply to 'Sudden Cardiac Death Following Use of the Synthetic Cannabinoid MDMB-CHMICA'. J Anal Toxicol. 2016;40(3):240–242.
   PubMed Web of Science ®Google Scholar
• Fujita Y, Koeda A, Fujino Y, et al. Clinical and toxicological findings of acute intoxication with synthetic cannabinoids and cathinones. Acute Med Surg. 2016;3(3):230–236.
   PubMed Web of Science ®Google Scholar
• Mochizuki A, Nakazawa H, Adachi N, et al. Identification and quantification of mepirapim and acetyl fentanyl in authentic human whole blood and urine samples by GC-MS/MS and LC-MS/MS. Forensic Toxicol. 2018;36(1):81–87.
   PubMed Web of Science ®Google Scholar
• Mochizuki A, Nakazawa H, Adachi N, et al. Postmortem distribution of mepirapim and acetyl fentanyl in biological fluid and solid tissue specimens measured by the standard addition method. Forensic Toxicol. 2019;37(1):27–33.
   PubMed Web of Science ®Google Scholar
• Sasaki C, Saito T, Shinozuka T, et al. A case of death caused by abuse of a synthetic cannabinoid N-1- naphthalenyl-1-pentyl-1H-indole-3-carboxamide. Forensic Toxicol. 2015;33(1):165–169.
   Web of Science ®Google Scholar
• Gugelmann H, Gerona R, Li C, et al. 'Crazy Monkey' poisons man and dog: human and canine seizures due to PB-22, a novel synthetic cannabinoid. Clin Toxicol (Phila). 2014;52(6):635–638.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Acute kidney injury associated with synthetic cannabinoid use-multiple states, 2012. MMWR Morb Mortal Wkly Rep. 2013;62(6):93–98.
   PubMed Web of Science ®Google Scholar
• Thornton SL, Wood C, Friesen MW, et al. Synthetic cannabinoid use associated with acute kidney injury. Clin Toxicol (Phila). 2013;51(3):189–190.
   PubMed Web of Science ®Google Scholar
• Rojek S, Korczyńska-Albert M, Kulikowska J, et al. New challenges in toxicology of new psychoactive substances exemplified by fatal cases after UR-144 and UR-144 with pentedrone administration determined by LC-ESI-MS-MS in blood samples. Arch Med Sadowej Kryminol. 2017;67(2):104–120.
   PubMedGoogle Scholar
• Adamowicz P, Gieroń J, Gil D, et al. The effects of synthetic cannabinoid UR-144 on the human body-a review of 39 cases. Forensic Sci Int. 2017;273:e18–e21.
   PubMed Web of Science ®Google Scholar
• Adamowicz P, Zuba D, Sekuła K. Analysis of UR-144 and its pyrolysis product in blood and their metabolites in urine. Forensic Sci Int. 2013;233(1-3):320–327.
   PubMed Web of Science ®Google Scholar
• Adamowicz P, Lechowicz W. The influence of synthetic cannabinoid UR-144 on human psychomotor performance-a case report demonstrating road traffic risks. Traffic Inj Prev. 2015;16(8):754–759.
   PubMed Web of Science ®Google Scholar
• Adamowicz P, Gieroń J, Gil D, et al. The prevalence of new psychoactive substances in biological material - a three-year review of casework in Poland. Drug Test Anal. 2016;8(1):63–70.
   PubMed Web of Science ®Google Scholar
• Shanks KG, Winston D, Heidingsfelder J, et al. Case reports of synthetic cannabinoid XLR-11 associated fatalities. Forensic Sci Int. 2015;252:e6–e9.
   PubMed Web of Science ®Google Scholar
• Lemos NP. Driving under the influence of synthetic cannabinoid receptor agonist XLR-11. J Forensic Sci. 2014;59(6):1679–1683.
   PubMed Web of Science ®Google Scholar